Advert - AstraZeneca – Case/0387/12/24

• Date posted
  24 October 2025
• Sanction
  Advertisement,
• Case number/s
  CASE/0387/12/24 - Complainant v AstraZeneca

For using a claim which misleadingly implied that Symbicort (budesonide/formoterol) Turbohaler with AIR (anti-inflammatory reliever) therapy was suitable for all newly diagnosed asthma patients aged 12 years and over, AstraZeneca was ruled in breach of the following clauses of the 2024 Code:

Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry

Clause 5.1 - Failing to maintain high standards at all times

Clause 6.1 - Making a misleading claim

Clause 6.2 - Making an unsubstantiated claim